In this interview, Jeffrey Cummings speaks to us about the current landscape around antibody therapeutics for Alzheimer’s disease.
In this review article, published in the journal Immunotherapy, the authors explore immunotherapy for neuroblastoma from therapeutic backbone to the latest discoveries.
A pioneering treatment, an antibody termed PRN100, is to be given to a patient with sporadic Creutzfeldt-Jakob disease for the first time.
In a direct comparison, ProMIS Neurosciences’ oligomer-selective antibody (PMN310) reveals a potential advantage over other antibody therapeutics.
Topline results from the Phase II study with BAN2401, an anti-amyloid beta antibody, have been reported in patients with early Alzheimer’s disease.
A preliminary study has revealed that a monoclonal antibody could prevent difficult-to-treat migraines in patients who have tried unsuccessfully to prevent them using other treatments.
Newly published data describe how Eli Lilly’s monoclonal antibody candidate has failed to significantly slow cognitive decline in patients with mild dementia due to Alzheimer’s disease.
Results from two Phase III clinical trials for erenumab and fremanezumab show that the monoclonal antibody therapies can cut frequency of migraine attacks in half.
Researchers have discovered that ocrelizumab can slow progression of symptoms and reduce new attacks in some patients with multiple sclerosis.